Answer
Jan 08, 2026 - 09:12 AM
Afrezza, an inhaled insulin, may cause lung-related side effects such as cough and throat irritation, and is not recommended for people with chronic lung diseases like asthma or COPD. It also has a shorter duration of action compared to some injectable insulins, which may require more frequent dosing and careful blood sugar monitoring. Additionally, long-term safety data is limited compared to traditional insulin therapies.
